Interleukin-6 (IL-6) is one of the most versatile signalling molecules in the human body. Produced by immune cells, fat tissue, and — critically — by working skeletal muscle, it acts as both a pro-inflammatory cytokine¹¹ pro-inflammatory cytokine
a signalling protein that promotes inflammation as part of the immune response and an anti-inflammatory myokine²² myokine
a cytokine released by muscle fibres during contraction, with systemic metabolic effects. The -174G/C promoter variant (rs1800795) sits 174 base pairs upstream of the IL6 gene on chromosome 7 and directly controls how much IL-6 your cells produce.

The Mechanism

The G allele at position -174 creates a promoter sequence with higher transcriptional activity³³ transcriptional activity
the rate at which a gene is read and converted into mRNA, which then becomes protein. In reporter gene assays, the G allele drives roughly 2-fold higher IL6 transcription compared to the C allele. This difference is mediated by a binding site for the transcription factor NF-1⁴⁴ NF-1
Nuclear Factor 1, a transcription factor that represses IL6 expression when bound to the -174C sequence: the C allele creates this repressive binding site, while the G allele abolishes it, allowing uninhibited transcription.

The consequence is straightforward: GG homozygotes produce the most IL-6 at baseline and under stress, CG heterozygotes produce intermediate amounts, and CC homozygotes produce the least. After stimulation by LPS⁵⁵ LPS
lipopolysaccharide, a bacterial endotoxin that triggers immune activation or IL-1, the G allele construct shows a robust increase in expression while the C allele construct remains largely unresponsive.

The Evidence

The -174G/C variant is one of the most studied cytokine polymorphisms, with evidence spanning cardiovascular disease, diabetes, exercise physiology, and ageing.

Cardiovascular risk: A meta-analysis of 74 studies with 86,229 subjects⁶⁶ meta-analysis of 74 studies with 86,229 subjects
Rodriguez-Perez et al. Interleukin 6 (rs1800795) gene polymorphism is associated with cardiovascular diseases. EXCLI Journal, 2019 found the C allele associated with increased cardiovascular disease risk (dominant model OR 1.12, 95% CI 1.07-1.18). The association was strongest for coronary artery disease (homozygous OR 1.50) and in Chinese populations (allelic OR 1.36).

Exercise-induced muscle damage: Yamin et al.⁷⁷ Yamin et al.
IL6 (-174) and TNFA (-308) promoter polymorphisms are associated with systemic creatine kinase response to eccentric exercise. Eur J Appl Physiol, 2008 demonstrated that CC homozygotes had a greater than 3-fold increased risk of massive creatine kinase⁸⁸ creatine kinase
an enzyme released from damaged muscle fibres; elevated CK after exercise is a marker of muscle damage (CK) response following eccentric exercise. Paradoxically, despite producing less IL-6 at baseline, the CC genotype appears to mount a more exaggerated muscle damage response.

Power athlete association: Ruiz et al.⁹⁹ Ruiz et al.
The -174 G/C polymorphism of the IL6 gene is associated with elite power performance. J Sci Med Sport, 2010 found the GG genotype overrepresented among elite power athletes (sprinters, jumpers, throwers) with an OR of 2.47 compared to controls, suggesting the higher inflammatory response may benefit explosive performance.

Diabetes: A comprehensive meta-analysis of 42,150 participants¹⁰¹⁰ comprehensive meta-analysis of 42,150 participants
IL-6 gene rs1800795 polymorphism and diabetes mellitus. Diabetol Metab Syndr, 2022 found the G allele associated with decreased type 2 diabetes risk in some populations, while the C allele showed a protective effect against fasting hyperglycaemia.

Glucose metabolism: A joint analysis of 17 studies¹¹¹¹ joint analysis of 17 studies
Huth et al. Joint analysis of individual participants' data from 17 studies on the association of the IL6 variant -174G>C. Ann Med, 2009 found C-allele carriers had significantly lower fasting glucose (-0.091 mmol/L, P=0.014).

Practical Implications

The functional consequence of this variant — higher or lower IL-6 production — has different implications depending on context:

For exercise recovery, GG carriers mount a stronger inflammatory response to training, which may support adaptation for power sports but also means managing recovery is important. CC carriers, despite lower baseline IL-6, show elevated muscle damage markers after eccentric exercise and may need longer recovery between intense sessions.

For cardiovascular health, the C allele carries modestly increased risk, making anti-inflammatory lifestyle measures and regular monitoring more relevant for CC and CG individuals.

For metabolic health, the C allele is associated with slightly lower fasting glucose, offering a minor metabolic advantage, while the G allele may carry a modest type 2 diabetes risk in certain populations.

Anti-inflammatory strategies — omega-3 fatty acids, adequate sleep, managing chronic stress, and maintaining a diet rich in colourful vegetables and polyphenols — are beneficial for all genotypes but especially important for GG carriers with higher baseline inflammation.

Interactions

The -174G/C variant (rs1800795) is in strong linkage disequilibrium with rs1800797 (-597G/A) in the same IL6 promoter region (r-squared = 0.92), meaning these two variants are almost always inherited together. The nearby rs1800796 (-572G/C) variant is an independent functional polymorphism that can compound the effect on IL-6 levels, though it is primarily polymorphic in East Asian populations. IL-6 signalling also interacts with the broader inflammatory cascade — TNF-alpha and CRP levels are influenced by IL-6, so this variant has downstream effects on systemic inflammation markers.

The complement factor H gene (CFH) on chromosome 1q31.3 is one of the most well-studied genetic determinants of age-related macular degeneration (AMD) — the leading cause of irreversible blindness in adults over 65. rs1831281 is an intronic variant at position 196,711,684 (GRCh38) in intron 10 of CFH, annotated at transcript position c.1337-2051. Like several other CFH intronic variants (rs551397, rs1329428, rs1410996), it serves as a haplotype tag SNP¹¹ haplotype tag SNP
a genetic marker that travels with a cluster of risk variants across generations because of their proximity on the chromosome, marking the complement-risk haplotype architecture of the CFH gene.

The C allele is both the GRCh38 reference allele and the major allele, found in ~80% of Europeans. Despite being common, it tags the complement-risk haplotype — a well-documented pattern in the CFH region where the ancestral, common haplotype carries the AMD-risk configuration. The T allele (~20% in Europeans, ~10% in Africans, ~39% in East Asians) marks the protective haplotype and is associated with better complement regulation at the retina and other tissues.

The Mechanism

Complement Factor H²² Complement Factor H
a 155 kDa plasma glycoprotein that is the primary fluid-phase regulator of the alternative complement pathway works by binding C3b (the activated form of complement component 3) and accelerating the decay of the amplification convertase C3bBb. At mucosal surfaces — including the retinal pigment epithelium (RPE) and Bruch's membrane — CFH suppresses chronic, low-grade complement activation that would otherwise damage host tissue. Age-related accumulation of oxidized lipids, advanced glycation end-products, and cellular debris provides a progressive stimulus for complement activation in the sub-retinal space.

rs1831281 itself does not alter any amino acid. Its disease significance comes from linkage disequilibrium with functionally important variants in the surrounding CFH haplotype block — principally the well-characterized complement-risk alleles at rs551397 (intron 1), rs1329428 (intron 14), and the coding missense variant Y402H (rs1061170, exon 9). The C allele at rs1831281 travels on the same chromosome as the risk alleles at these adjacent positions; by carrying the C allele, a person is statistically more likely to also carry the full complement-risk haplotype configuration, which cumulatively reduces CFH's protective function at retinal and other complement-exposed surfaces.

A correction notice was issued for the Hughes et al. 2006 Nature Genetics study³³ Hughes et al. 2006 Nature Genetics study
A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nature Genetics 2006 regarding the allele designations of rs1831281 in Figure 1, confirming that this SNP was genotyped and used in CFH haplotype block analyses of AMD risk.

The Evidence

The AMD association of the CFH locus is one of the most replicated findings in complex disease genetics. Klein et al. 2005⁴⁴ Klein et al. 2005
Science — genome-wide screen of 116,000+ SNPs in 96 cases and 50 controls identified the CFH intronic region as the primary AMD susceptibility locus, with homozygous risk carriers showing a 7.4-fold increased likelihood of AMD. The CFH haplotype block where rs1831281 resides (intron 10, c.1337-2051) is part of this broader risk architecture.

Hageman et al. 2005⁵⁵ Hageman et al. 2005
PNAS — 900 AMD cases and controls further characterized the CFH risk haplotype, finding it in 50% of AMD cases versus 29% of controls (OR 2.46), with homozygous risk carriers comprising 24% of cases but only 8% of controls. Critically, risk and protective haplotypes were identified across the entire CFH gene including its intronic regions — the same structure encompassing rs1831281.

The large Lu et al. 2018 meta-analysis⁶⁶ Lu et al. 2018 meta-analysis
53 studies, 53,774 AMD patients, 56,973 controls. Genet Test Mol Biomarkers 2018 demonstrated that T-allele carrying CFH haplotype SNPs in this region are associated with OR=0.53 for AMD protection (95% CI 0.45–0.61), underscoring the magnitude of protection conferred by the complement-protective haplotype to which the T allele of rs1831281 belongs.

Regarding cardiovascular disease, the Sofat et al. 2010 meta-analysis⁷⁷ Sofat et al. 2010 meta-analysis
~48,000 participants, 9,097 CHD cases found that CFH genotype was not associated with coronary heart disease (pooled OR 1.02, 95% CI 0.91–1.13 for the Y402H risk allele). This meta-analysis result is expected to extend to other CFH haplotype-tag SNPs including rs1831281: the complement-inflammation pathway operates through AMD-specific retinal mechanisms rather than classical atherosclerotic pathways.

Practical Actions

The C allele at rs1831281 is clinically useful primarily as part of a multi-variant CFH risk profile. Its significance is amplified when co-occurring with risk alleles at rs1061170 (Y402H), rs551397, and rs800292 — and diminished when the protective T allele is present, which partially offsets the complement-risk haplotype background.

For CC homozygotes, the primary actionable implications are identical to those for other CFH complement-risk haplotype SNPs: earlier ophthalmologic surveillance, targeted macular carotenoid supplementation, and omega-3 optimization to reduce complement-driven retinal inflammation. Smoking cessation is particularly important as tobacco compounds CFH-pathway complement activation at the retina through oxidative and endothelial mechanisms.

Interactions

rs1831281 is in linkage disequilibrium with multiple CFH haplotype SNPs across the gene: rs551397 (intron 1), rs1329428 (intron 14), and the Y402H coding variant rs1061170. The AMD-risk C allele at rs1831281 is expected to co-occur with the risk alleles at these positions in most chromosomes carrying the risk haplotype, making it an additive signal rather than an independent risk factor. The most clinically meaningful two-locus interaction is with ARMS2 (rs10490924), where complement dysregulation (CFH) plus retinal oxidative stress (ARMS2) converge on two independent AMD pathogenesis pathways with synergistic risk elevation.

Interleukin-6 is the cytokine most consistently elevated in older adults — a key driver of inflammaging¹¹ inflammaging
the chronic low-grade inflammation that accumulates with age and underlies most age-related diseases, from atherosclerosis to Alzheimer's to type 2 diabetes. Within the IL6 gene lies a lesser-known intronic variant, rs2069837, whose effect on aging biology is not what you might expect: rather than directly changing IL-6 protein structure or promoter activity, it operates through a remarkable long-range genomic mechanism that reaches half a megabase away.

The Mechanism

rs2069837 sits in intron 2 of IL6, within an active enhancer region²² enhancer region
a stretch of non-coding DNA that can dramatically increase or decrease expression of target genes, often over large genomic distances. In 2019, researchers discovered that this variant doesn't primarily regulate IL6 itself — it regulates GPNMB³³ GPNMB
glycoprotein NMB, an anti-inflammatory protein expressed in macrophages that dampens immune overactivation and promotes tissue resolution, located approximately 520 kilobases away on the same chromosome.

The mechanism operates through chromatin looping: CTCF⁴⁴ CTCF
CCCTC-binding factor, a structural protein that creates physical contact points between distant genomic regions mediates a long-range interaction that brings the rs2069837 enhancer into physical contact with the GPNMB promoter. The A allele of rs2069837 preferentially recruits the MEF2-HDAC repressive complex⁵⁵ MEF2-HDAC repressive complex
a protein complex that silences gene expression by compacting chromatin into a transcriptionally inactive state, suppressing GPNMB expression in monocyte-derived macrophages. The G allele disrupts this repressive recruitment, allowing GPNMB to be expressed normally. ⁶⁶ Kong et al. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex. Ann Rheum Dis, 2019

The downstream consequence is that A-allele carriers have lower macrophage GPNMB expression, which in turn alters the balance of IL-6 signalling — the A allele environment allows higher effective IL-6 activity because the anti-inflammatory brake (GPNMB) is partially removed. The G allele restores the brake.

The Evidence

Longevity GWAS: A genome-wide association study in Han Chinese centenarians⁷⁷ genome-wide association study in Han Chinese centenarians
Zeng et al. Novel loci and pathways significantly associated with longevity. Scientific Reports, 2016 found rs2069837 reached genome-wide significance (P = 1.80 × 10⁻⁹) as a longevity locus, with the G allele significantly less frequent among centenarians than among middle-aged controls (OR = 0.61). This indicates the G allele is paradoxically the longevity-deleterious allele at this locus — those who live longest tend to carry more A alleles.

COVID-19 severity: The G allele's effect on GPNMB/IL-6 has an acute protective benefit in some inflammatory contexts. A GWAS of critical COVID-19⁸⁸ GWAS of critical COVID-19
Gong et al. A genetic variant in IL-6 lowering its expression is protective for critical patients with COVID-19. Signal Transduct Target Ther, 2022 found G-allele carriers had dramatically lower risk of critical illness (OR = 0.41 in discovery cohort; OR = 0.49 in combined analysis, P = 4.64 × 10⁻¹⁶). The mechanism confirmed: the G allele decreased MEF2a binding and increased GPNMB expression, resulting in lower IL-6. The protective effect was stronger in males.

Hepatocellular carcinoma: In the context of chronic liver disease, the G allele confers risk rather than protection. A meta-analysis of 13 case-control studies⁹⁹ meta-analysis of 13 case-control studies
Emami Aleagha et al. Association between IL-6 polymorphisms and HCC susceptibility. Clin Exp Hepatol, 2020 found the GG genotype associated with 2.25-fold elevated hepatocellular carcinoma risk (OR 2.25, 95% CI 1.18–4.29). This aligns with GPNMB's dual roles: GPNMB suppresses inflammatory tissue damage, but also blunts immune surveillance against tumour cells.

Alzheimer's disease: A Taiwanese case-control study¹⁰¹⁰ Taiwanese case-control study
Chen et al. Sequence variants of IL-6 are significantly associated with a decreased risk of late-onset Alzheimer's disease. J Neuroinflammation, 2012 analyzed IL6 haplotypes including rs2069837 in 266 AD cases and 444 controls. The strongest protective signal (adjusted OR = 0.65) came from a haplotype defined by rs1800796 and rs1524107 rather than rs2069837 directly. Hypertension significantly modified the association.

Practical Implications

This variant presents a genuine paradox: the G allele protects against acute inflammatory overreaction (severe COVID-19, autoimmune vasculitis) but is underrepresented among extreme long-livers in East Asian populations and associates with elevated hepatocellular carcinoma risk. This reflects GPNMB's dual nature — an anti-inflammatory signal that also dampens immune surveillance.

For AA homozygotes (the genotype of most centenarians), lower GPNMB expression maintains stronger macrophage inflammatory tone. This may be advantageous for cancer immune surveillance and, over decades, for the type of calibrated immune competence associated with exceptional longevity. However, the tradeoff is potentially higher IL-6 activity, making monitoring of inflammatory markers and IL-6-related disease risk more important.

For AG heterozygotes, intermediate GPNMB expression places them between the extremes. The clinical implications are modest and context-dependent.

For GG homozygotes (rare, ~1% of most populations), higher GPNMB suppresses IL-6 and may offer protection in acute inflammatory settings, but the rare homozygous state has been associated with elevated HCC risk and is uncommon in centenarians.

Interactions

rs2069837 exists within the broader IL6 gene context alongside the well-characterised promoter variant rs1800795 (-174G/C), which is in the GeneOps database under the fitness-body category. These two variants operate through distinct mechanisms and are not in strong linkage disequilibrium — rs1800795 affects promoter transcriptional activity directly, while rs2069837 acts through the distal GPNMB enhancer loop. Combined effects of rs1800795 (direct IL-6 production) and rs2069837 (GPNMB-mediated IL-6 modulation) on inflammaging have not been formally studied as a compound genotype. The interaction with IL-10 variants (particularly rs1800871) has been studied in epidemiological contexts, with IL6 rs2069837 × IL10 haplotype combinations showing region-specific effects on disease susceptibility.

SREBP-2 (sterol regulatory element-binding protein 2), encoded by the SREBF2 gene on chromosome 22, is the master transcription factor of cholesterol homeostasis. It directly controls expression of HMGCR¹¹ HMGCR
HMG-CoA reductase — the rate-limiting enzyme in cholesterol biosynthesis and the target of all statin drugs, LDLR²² LDLR
the LDL receptor that clears LDL cholesterol from the bloodstream, and more than 30 other genes in the cholesterol synthesis and uptake pathways. The rs2228314 variant (G1784C) is a missense change that substitutes glycine for alanine at protein position 595 and has been linked to cardiovascular disease risk and altered cholesterol regulation across multiple populations.

The Mechanism

The Gly595Ala substitution falls in the carboxyl-terminal regulatory domain of SREBP-2, the region that physically interacts with SCAP³³ SCAP
SREBP cleavage-activating protein — the sterol sensor that escorts SREBP-2 from the ER to the Golgi for proteolytic activation. Under normal cholesterol conditions, SCAP holds SREBP-2 anchored to the endoplasmic reticulum membrane, suppressing transcriptional activity. When cellular cholesterol falls — as happens during statin treatment — SCAP escorts SREBP-2 to the Golgi, where it is cleaved and the active transcription factor enters the nucleus to upregulate HMGCR, LDLR, and other cholesterol-response genes.

The Gly595Ala change is located at a position in the C-terminal domain involved in SCAP WD-repeat interactions. Bioinformatic analysis suggests the mutation position is not strongly conserved, but in vitro studies show the Ala-595 isoform may diminish SREBF2 proteolytic cleavage⁴⁴ diminish SREBF2 proteolytic cleavage
Haas et al. — the p.A595G (C allele) polymorphism diminishes SREBF2 cleavage in vitro and is associated with higher cholesterol levels in polygenic hypercholesterolemia, potentially blunting the cholesterol-sensing feedback loop.

The Evidence

A study of early-onset myocardial infarction⁵⁵ study of early-onset myocardial infarction
Friedlander et al. SREBP-2 and SCAP isoforms and risk of early onset myocardial infarction. Atherosclerosis, 2008 in 257 women and 320 men (ages 18–59 for women, 18–49 for men) found that women homozygous for the 595A (Ala, C allele) isoform had nearly twice the risk of a first MI compared to 595G homozygotes (OR 1.95, 95% CI 1.07–3.54). In men, the 595A isoform was associated with increased MI risk per-allele (OR 1.63, 95% CI 1.26–2.12), with the effect modified by the co-inherited SCAP 2386A>G variant.

A sudden cardiac death study⁶⁶ sudden cardiac death study
Nakhjavani et al. Expression of SREBF2 and SCAP in human atheroma and association with sudden cardiac death. Thrombosis Journal, 2009 found that men carrying both the SREBF2 C allele and the SCAP G allele (rs12487736) had a 2.68-fold elevated risk of SCD (95% CI 1.07–6.71, p=0.035) compared to those carrying C allele alone, pointing to a gene-gene interaction that amplifies cardiovascular risk.

A case-control study⁷⁷ case-control study
Vargas-Alarcon et al. SREBF1c and SREBF2 gene polymorphisms and acute coronary syndrome in Mexican population. PLoS One, 2019 in 614 ACS patients and 689 healthy controls of Mexican-Amerindian descent found the G allele associated with ACS risk under recessive (OR 1.78, p=0.03) and additive (OR 1.27, p=0.04) models. The apparent reversal — G risk in Mexicans versus C risk in Europeans — likely reflects the fact that the G allele is the minor allele in Latino populations (~35%), where homozygous GG individuals represent a distinct risk stratum, while C is minor in Europeans (~26%).

A carotid intima-media thickness study⁸⁸ carotid intima-media thickness study
characterization of SREBP-2 gene polymorphisms: role in atherosclerosis. Atherosclerosis, 2003 in 655 asymptomatic men found the 1784G>C variant significantly associated with increased IMT — a marker of subclinical atherosclerosis — without detectable changes in plasma lipid levels, suggesting the variant may influence vascular risk through mechanisms beyond simple LDL elevation.

A NAFLD study⁹⁹ NAFLD study
Wang et al. Relationship of SREBP-2 rs2228314 G>C polymorphism with NAFLD in Han Chinese. Genet Test Mol Biomarkers, 2014 found homozygous GG genotype associated with increased risk of non-alcoholic fatty liver disease in 300 NAFLD cases versus 160 controls (p<0.001), suggesting the variant may also influence hepatic lipid accumulation through SREBP-2 target gene dysregulation.

ClinVar classifies the C (alternate) allele as benign based on population frequency data, with no pathogenic submissions. The clinical associations above are from GWAS and case-control studies — this variant is a risk modifier, not a disease-causing mutation.

Practical Actions

Carriers of the C allele at this locus, particularly those homozygous (CC), may have a subtly altered cholesterol-sensing feedback loop. Monitoring LDL cholesterol and tracking response to dietary changes or statin therapy is a reasonable proactive step. Those with the CC genotype may show attenuated statin response compared to GG individuals, given SREBP-2's central role in statin-induced LDLR upregulation — though the clinical evidence for this specific pharmacogenomic interaction is still emerging.

Dietary phytosterols (plant sterols/stanols from fortified foods or supplements) provide an additional cholesterol-lowering pathway that does not depend on SREBP-2 activity, making them a relevant strategy for CC genotype carriers who want to augment cholesterol management.

Interactions

The most clinically relevant interaction is with SCAP rs12487736 (2386A>G). The SCAP protein is the direct chaperone and sterol sensor for SREBP-2; variants in SCAP that alter its interaction with SREBP-2 compound the effect of this variant. Carrying risk alleles at both SREBF2 rs2228314 and SCAP rs12487736 appears to substantially elevate sudden cardiac death risk in men (OR 2.68), beyond what either variant contributes alone. This gene-gene interaction is a strong candidate for a compound action.

This variant also sits in the same cholesterol-homeostasis pathway as APOE (rs429358, rs7412). APOE E4 carriers who also carry the SREBF2 C allele may have compounded LDL clearance impairment — the APOE variant impairs LDL receptor binding affinity while the SREBF2 variant may blunt transcriptional upregulation of LDLR expression.

The ATG16L1 gene provides instructions for making a protein essential to autophagy, the cellular recycling system that clears out damaged components and invading bacteria. The T300A variant¹¹ The T300A variant
This threonine-to-alanine substitution at position 300 is one of the most replicated genetic risk factors for Crohn's disease, first identified in a genome-wide association study in 2007 and subsequently confirmed in dozens of independent cohorts worldwide. In the gut, ATG16L1 plays a critical role in Paneth cells, specialized epithelial cells that secrete antimicrobial peptides and maintain the intestinal barrier. The T300A variant impairs this function, allowing bacteria to persist when they would normally be destroyed.

The Mechanism

The T300A variant sits near a caspase-3 cleavage site²² The T300A variant sits near a caspase-3 cleavage site
Amino acids 296-299 form a caspase cleavage motif, and the T300A substitution significantly increases the protein's susceptibility to caspase-3-mediated degradation during cellular stress. When cells experience metabolic stress, death receptor activation, or starvation, caspase-3 degrades the T300A variant more rapidly than wild-type ATG16L1, resulting in diminished autophagy. This leaves epithelial cells less able to clear invading bacteria like Salmonella and Yersinia enterocolitica. Studies in human epithelial cells show the T300A variant has markedly decreased efficiency³³ the T300A variant has markedly decreased efficiency
The ala300-containing variant showed decreased capture of internalized Salmonella within autophagosomes compared to the wildtype thr300-containing variant in capturing bacteria within autophagosomes. The variant also disrupts the WD40 domain's ability to interact with proteins like TMEM59, further impairing unconventional autophagy pathways.

The Evidence

Multiple meta-analyses confirm the T300A association with Crohn's disease⁴⁴ Multiple meta-analyses confirm the T300A association with Crohn's disease
Meta-analysis of 30,606 IBD patients found the G allele was a risk factor (OR 1.23, 95% CI: 1.09-1.39, p=0.001) while the A allele was protective (OR 0.74, 95% CI: 0.72-0.77, p<0.001). The association is strongest in Caucasian populations from North America, Europe, and Latin America, with minimal to no association observed in Asian populations. CD patients carrying the G allele are significantly more predisposed to perianal disease⁵⁵ CD patients carrying the G allele are significantly more predisposed to perianal disease
OR 1.21, 95% CI: 1.07-1.38, p=0.003, one of the more severe and treatment-resistant manifestations of Crohn's. A 2025 meta-analysis found the G allele increases CD risk worldwide⁶⁶ A 2025 meta-analysis found the G allele increases CD risk worldwide
OR 1.33, 95% CI: 1.29-1.37, with GG homozygotes showing higher risk than AG heterozygotes. The variant also alters gut microbiota composition—studies in knock-in mice show increased Bacteroides ovatus and elevated Th17 and Th1 immune cells⁷⁷ studies in knock-in mice show increased Bacteroides ovatus and elevated Th17 and Th1 immune cells
Changes occur before disease onset, suggesting T300A contributes to dysbiosis and immune infiltration prior to symptoms.

Practical Implications

This variant doesn't cause Crohn's disease on its own—it's a susceptibility factor that increases risk in the presence of environmental triggers like smoking, certain infections, or dietary patterns that stress the gut. For those with the GG genotype (about 19% of Europeans), maintaining gut barrier integrity becomes especially important. This means prioritizing dietary fiber, fermented foods, and avoiding pro-inflammatory processed foods and excessive antibiotic use. Regular monitoring for early signs of inflammatory bowel disease (persistent diarrhea, abdominal pain, blood in stool) allows for earlier intervention. The variant's impact on bacterial clearance also suggests that individuals with GG may benefit from strategies that support innate immunity and gut microbial diversity.

Interactions

ATG16L1 T300A interacts with other Crohn's disease susceptibility genes through multiple pathways. Multidimensionality reduction analysis shows interaction between ATG16L1, IBD5 (rs6596075), and IL23R (rs10889677) risk alleles⁸⁸ Multidimensionality reduction analysis shows interaction between ATG16L1, IBD5 (rs6596075), and IL23R (rs10889677) risk alleles
MDR analysis suggested an interaction between IBD5, ATG16L1, and IL23R risk alleles, with combined carriage of multiple risk variants substantially increasing CD risk. NOD2 (rs17221417) is particularly important— NOD2 recruits ATG16L1 to sites of bacterial entry⁹⁹ NOD2 recruits ATG16L1 to sites of bacterial entry, so NOD2 mutations combined with ATG16L1 T300A produce a synergistic defect in bacterial autophagy. Individuals homozygous for risk alleles at ATG16L1, IBD5, and NOD2 face approximately 20-fold higher CD risk¹⁰¹⁰ Individuals homozygous for risk alleles at ATG16L1, IBD5, and NOD2 face approximately 20-fold higher CD risk
OR 20.4, CI 8.71-47.7 compared to those carrying none of these variants. IL23R variants also show statistical interaction, as IL23R regulates the Th17 immune response that becomes dysregulated when ATG16L1-mediated bacterial clearance fails.

The yellowing of the skin in jaundice has made bilirubin notorious as a toxin. But at physiological concentrations, bilirubin functions as one of the body's most potent endogenous antioxidants — and your genome partly determines how much of it you carry. The rs2361502 variant in the MROH2A gene, situated directly adjacent to the UGT1A gene cluster¹¹ UGT1A gene cluster
A family of enzymes on chromosome 2q37.1 responsible for glucuronidating bilirubin — conjugating it so the liver can excrete it in bile on chromosome 2q37.1, is one of the genetic markers most consistently associated with circulating bilirubin concentrations in genome-wide association studies.

The Mechanism

rs2361502 is an intronic variant within MROH2A (maestro heat-like repeat family member 2A, also annotated as HEATR7B1), a gene whose protein product is poorly characterised at the functional level. The variant itself is unlikely to alter MROH2A protein function. Rather, because MROH2A sits immediately adjacent to the UGT1A locus, rs2361502 is a tag SNP²² tag SNP
A tag SNP is a marker variant in strong linkage disequilibrium with a functional variant; it tracks the functional variant across populations even though it has no effect itself that captures regulatory variation in UGT1A1 — specifically variation that modulates how efficiently the liver conjugates bilirubin for excretion. Carriers of the C allele have lower hepatic UGT1A1 activity in this region, resulting in slower bilirubin clearance and thus higher steady-state serum concentrations. Each copy of the C allele raises total serum bilirubin by roughly 0.096–0.098 mg/dL.

At physiological concentrations (0.2–1.2 mg/dL), bilirubin scavenges reactive oxygen species³³ reactive oxygen species
Unstable molecules such as superoxide, hydroxyl radical, and peroxynitrite produced during normal metabolism and during inflammation; excessive ROS damages DNA, lipids, and proteins and inhibits LDL oxidation, a key early step in atherosclerosis. It also suppresses the NADPH oxidase system and blunts inflammatory cytokine signalling.

The Evidence

The strongest direct evidence for rs2361502 comes from a genome-wide association study of 430 subjects with metabolic syndrome⁴⁴ genome-wide association study of 430 subjects with metabolic syndrome
Coltell O et al. Genome-Wide Association Study (GWAS) on Bilirubin Concentrations in Subjects with Metabolic Syndrome. Nutrients, 2019 drawn from the PREDIMED Plus-Valencia cohort. rs2361502 reached genome-wide significance (p=4×10⁻⁸), with each C allele increasing bilirubin by 0.096 mg/dL. A larger signal (p=7×10⁻²³, beta=0.098 mg/dL per C allele) emerged from the eMERGE network analysis by Bielinski et al., confirming the locus in a population with thousands of individuals. A PheWAS in HIV-positive individuals⁵⁵ PheWAS in HIV-positive individuals
Moore CB et al. Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis, 2015 from AIDS Clinical Trials Group protocols (n=2,547) independently replicated the bilirubin association (p=3×10⁻⁶).

The clinical significance of chronically elevated bilirubin is well-established. A meta-analysis of 16 observational studies in 175,911 participants⁶⁶ meta-analysis of 16 observational studies in 175,911 participants
Nano J et al. Association of circulating total bilirubin with the metabolic syndrome and type 2 diabetes. Diabetes Metab, 2016 found those in the highest bilirubin tertile had roughly 30% lower odds of metabolic syndrome (OR 0.70, 95% CI 0.62–0.78) and 23% lower odds of type 2 diabetes (OR 0.77, 95% CI 0.67–0.87) compared to those with the lowest bilirubin. Similarly, both retrospective and prospective studies consistently show an inverse relationship between bilirubin and cardiovascular disease events, with individuals carrying UGT1A1*28 — the canonical low-clearance allele for which rs2361502 serves as a marker — having significantly lower CVD risk⁷⁷ significantly lower CVD risk
Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk. Atherosclerosis, 2008 than wild-type carriers.

It should be noted that Mendelian randomization has not yet confirmed a strong causal role for bilirubin in cardiovascular protection: a 2015 analysis using rs6742078 as an instrumental variable found OR 1.03 (95% CI 0.98–1.09) for coronary heart disease per SD increase in bilirubin, suggesting some of the observational benefit may reflect confounding. The protective signal is robust observationally but causal confirmation awaits larger MR studies.

Practical Actions

Carriers of the CC genotype maintain chronically higher bilirubin concentrations, which appear to confer modest metabolic protection. The main clinical value of knowing this genotype is interpreting blood test results accurately: mildly elevated bilirubin (up to ~2 mg/dL in the absence of symptoms) is a benign, genetically-driven phenotype rather than a sign of liver disease. Additionally, behaviours and substances that increase oxidative stress — smoking, very high alcohol intake, or chronic exposure to environmental oxidants — will consume bilirubin's antioxidant capacity, eroding the genetic advantage.

CT heterozygotes have intermediate bilirubin and a similar but attenuated benefit.

TT homozygotes have the reference (lower) bilirubin. This does not imply disease risk; average bilirubin concentrations are already within the protective range for most people. Maintaining low oxidative stress through diet rich in antioxidant micronutrients (vitamins C and E, polyphenols) partially compensates for the reduced endogenous bilirubin buffering.

Interactions

rs2361502 is in linkage disequilibrium with several UGT1A1 variants, including rs887829 and rs6742078, which are the canonical functional markers for Gilbert syndrome and the UGT1A1*28 promoter haplotype. Carriers of multiple C-raising alleles at this locus (e.g., rs2361502 CC combined with rs887829 minor-allele homozygosity) likely experience additive bilirubin elevation. No published compound-genotype analysis of rs2361502 combined with other UGT1A1 variants has been reported, but the biological logic of additive UGT1A1 suppression is well established.

Deep inside every monoaminergic synapse, an enormous scaffolding protein called Piccolo acts as the master organiser of neurotransmitter release. Piccolo¹¹ Piccolo
Encoded by PCLO, a presynaptic cytomatrix protein (~550 kDa) that anchors at the active zone and coordinates synaptic vesicle docking, priming, and endocytic recycling is particularly critical at serotonergic and dopaminergic synapses in limbic circuits relevant to mood regulation. The rs2522833 variant (p.Ser4814Ala) sits within Piccolo's C2A domain — a calcium-sensing module that governs how efficiently vesicles are made available for release — and the resulting amino acid substitution has been linked to altered HPA axis regulation, depression vulnerability, and modified response to antidepressant treatment.

The Mechanism

The C2A domain of Piccolo binds calcium with low affinity, acting as a sensor that modulates the readily releasable pool of synaptic vesicles during sustained neural firing. When serine at position 4814 is replaced by alanine, the local conformation of the C2A domain changes subtly — serine carries a hydroxyl group capable of hydrogen bonding that alanine lacks. Functional studies in mouse models carrying the Ser→Ala substitution found two cellular-level consequences: increased synaptic Piccolo protein levels and approximately 30% higher excitatory synaptic transmission in cultured neurons²² increased synaptic Piccolo protein levels and approximately 30% higher excitatory synaptic transmission in cultured neurons
Giniatullina et al. Neuroscience, 2015 (PMID 26045179). Calcium-dependent phospholipid binding and total vesicle pool size were unaffected. The net result at the human level is a presynaptic system with mildly altered monoamine release dynamics — likely expressed most clearly under demand conditions such as chronic stress, acute stressors, or pharmacological challenge rather than at rest.

The C allele (encoding Ala-4814) is the risk variant, while the A allele (encoding Ser-4814) represents the reference state. The PCLO gene lies on chromosome 7q11, and rs2522833 is on the minus strand; the plus-strand alleles reported in genome files are A (Ser, reference) and C (Ala, risk).

The Evidence

The genetic signal for PCLO and major depressive disorder has been replicated across multiple independent cohorts. The Rotterdam Study found rs2522833 associated with DSM-defined depressive disorders (P=0.0025) and achieved genome-wide significance (P=1.93×10⁻⁹) in meta-analysis across three population cohorts³³ found rs2522833 associated with DSM-defined depressive disorders (P=0.0025) and achieved genome-wide significance (P=1.93×10⁻⁹) in meta-analysis across three population cohorts
Hek et al. Human Molecular Genetics, 2010. A subsequent Dutch twin-registry study confirmed genome-wide significance at the PCLO locus (rs2715157, p=2.91×10⁻⁸; gene-level p=1.48×10⁻⁷) comparing 1,942 lifetime MDD cases against 4,565 controls⁴⁴ comparing 1,942 lifetime MDD cases against 4,565 controls
Mbarek et al. Twin Research and Human Genetics, 2017.

Two independent lines of evidence link rs2522833 specifically to HPA axis function. In 205 MDD inpatients treated with antidepressants over four weeks, C-allele carriers showed significantly greater reductions in cortisol and ACTH levels during treatment (p=0.01–0.02, η²=0.014–0.031) compared to AA carriers, whose HPA measures barely shifted⁵⁵ C-allele carriers showed significantly greater reductions in cortisol and ACTH levels during treatment (p=0.01–0.02, η²=0.014–0.031) compared to AA carriers, whose HPA measures barely shifted
Schuhmacher et al. IJNP, 2011. Clinical response (symptom scores) was similar across genotypes, suggesting that the HPA modulation is a biological signal independent of whether the treatment works subjectively. In healthy adults, a study of 66 young volunteers found C-allele carriers had a blunted cortisol awakening response (CAR AUCinc: 282 vs 467, p=0.042) and higher neuroticism scores compared to AA carriers⁶⁶ C-allele carriers had a blunted cortisol awakening response (CAR AUCinc: 282 vs 467, p=0.042) and higher neuroticism scores compared to AA carriers
Kuehner et al. Translational Psychiatry, 2011 — indicating that the HPA impact is present even without depression, suggesting it precedes rather than results from the disorder.

Structural brain imaging reinforced the picture. In drug-naive first-episode MDD patients, C-allele carriers showed significantly smaller left temporal pole gray matter volume (P=0.003) compared to healthy C-carrier controls, with elevated plasma cortisol (12.76±6.10 vs 9.31±3.60 nmol/L, P=0.045)⁷⁷ C-allele carriers showed significantly smaller left temporal pole gray matter volume (P=0.003) compared to healthy C-carrier controls, with elevated plasma cortisol (12.76±6.10 vs 9.31±3.60 nmol/L, P=0.045)
Igata et al. Translational Psychiatry, 2017. The left temporal pole is implicated in emotional memory, social cognition, and the interface between affect and cognition — all functions disrupted in depression. Personality studies further showed C-allele carriers score higher on Harm Avoidance and lower on Novelty Seeking⁸⁸ Harm Avoidance and lower on Novelty Seeking
Minelli et al. Journal of Affective Disorders, 2012 — a temperament configuration associated with fearfulness, fatigue, and reduced reward-seeking that predisposes to both depression and anxiety.

It is important to note that the PCLO association has not replicated in all large GWAS efforts. The variant's per-allele effect is modest and polygenic. The evidence is strongest for the HPA-axis phenotype and antidepressant response modulation; the direct depression risk signal is moderate rather than established.

Practical Actions

Because the C allele's main documented effects are on HPA axis reactivity and antidepressant treatment response, actionable strategies centre on supporting HPA regulation and optimising SSRI response monitoring. The blunted cortisol awakening response in C-carriers suggests that the hypothalamic-pituitary-adrenal circuit is already under-responding rather than over-responding — a pattern associated with burnout and emotional exhaustion rather than acute stress reactivity. Practices that support healthy HPA axis tone (robust awakening routines that reinforce the cortisol awakening response, phosphatidylserine supplementation to normalise HPA sensitivity) are relevant. For C-carriers undergoing SSRI or SNRI treatment, the Schuhmacher data suggests that HPA biomarkers (morning cortisol) change detectably during treatment — tracking this can provide an early biological signal of treatment engagement.

Interactions

The most clinically meaningful gene-gene interactions for rs2522833 are with other monoaminergic system variants. The serotonin transporter promoter polymorphism 5-HTTLPR (SLC6A4) and COMT rs4680 (Val158Met) both influence monoaminergic synaptic tone and have been studied alongside PCLO rs2522833 in antidepressant response contexts. Carriers of C-allele in PCLO combined with SLC6A4 s-allele (reduced serotonin reuptake capacity) represent a theoretically compounded serotonergic vulnerability. CREB1 rs4675690, another early MDD GWAS candidate linked to transcriptional regulation of monoamine pathways, represents an additional potential interaction partner. These combinations have not yet been studied in adequately powered samples and should be considered hypothesis-generating rather than established.

The heart's pumping power depends on the precise choreography of sarcomeric proteins — molecular motors that convert ATP into coordinated contraction. Beta-myosin heavy chain¹¹ Beta-myosin heavy chain
Encoded by MYH7; the dominant myosin isoform in adult ventricular cardiomyocytes, making up roughly 30% of total ventricular protein mass is the central force-generator of this system. rs267606908 replaces an aspartate at position 906 of this protein with a glycine — a conservative-looking swap that nonetheless disrupts the motor's kinetics profoundly. Carriers of the C allele face a substantially elevated risk of hypertrophic cardiomyopathy (HCM)²² hypertrophic cardiomyopathy (HCM)
A structural heart disease defined by unexplained left ventricular hypertrophy not caused by pressure overload; the most common inherited cardiac condition, affecting 1 in 500 people overall, and are at risk for sudden cardiac death and progressive heart failure.

The Mechanism

Beta-myosin works through a mechanochemical cycle: ATP binds to the motor domain, hydrolysis cocks the lever arm, actin binding triggers force release (the power stroke), and ADP dissociation resets the cycle. The Asp906 residue sits in a region critical for Switch-2 closure³³ Switch-2 closure
A structural movement within the myosin motor domain that gates the release of the hydrolysis products; defective Switch-2 closure slows the ATPase cycle and traps the motor in a force-producing state. Replacing Asp906 with glycine disrupts this geometry in two measurable ways: the motor's maximum ATPase rate drops ~30%, and the hydrolysis step itself is slowed 3-fold compared to wild-type.

Yet paradoxically, force production increases. Single-molecule laser trap experiments⁴⁴ Single-molecule laser trap experiments
Sommese et al. used optical tweezers to measure the force a single myosin molecule produces during its power stroke; the technique isolates individual motor events from the ensemble showed D906G myosin generates approximately 50% more force per power stroke (2.1 vs 1.4 piconewtons) than wild-type, and ensemble loaded-motility assays confirmed this hypercontractile phenotype. In muscle fiber studies, actin filaments translocated 34% faster over Asp906Gly myosin compared to wild-type. The result is a motor that generates excessive force while cycling inefficiently — a combination that imposes chronic mechanical stress on cardiomyocytes, activates pro-fibrotic signaling cascades, and drives pathological hypertrophy.

A 2024 transgenic pig model reproduced the human phenotype with high fidelity. Animals carrying the D906G mutation⁵⁵ D906G mutation
Modeled in the closely related MYH7 isoform of the pig heart developed ventricular fibrosis, cardiomyocyte loss, and activated TGF-β/Smad2/3, ERK1/2, and Nox4/ROS/NF-κB signaling — all pathways implicated in HCM progression and end-stage cardiac remodeling.

The Evidence

rs267606908 was reviewed and classified as pathogenic by the ClinGen Cardiomyopathy Variant Curation Expert Panel⁶⁶ ClinGen Cardiomyopathy Variant Curation Expert Panel
An NIH-funded consortium of cardiomyopathy genetics experts that systematically reviews variant evidence using standardized ACMG/AMP criteria in December 2016. With 18 independent ClinVar submissions all converging on "pathogenic" status, this is among the better-curated HCM variants in the genome.

Clinical penetrance data are sobering. A Chinese family study⁷⁷ Chinese family study
Wang et al. 2024, published in the Chinese Heart Journal, studying 5 unrelated probands and their families found 12 of 13 mutation carriers diagnosed with HCM, with 2 sudden cardiac deaths, 2 SCD-survival events, and 3 deaths before age 30 among the families. A earlier US biochemical study estimated penetrance at 25%⁸⁸ estimated penetrance at 25%
Alpert et al. 2005; penetrance varied from 25% for Asp906Gly to 46% for Leu908Val among family members examined, noting that "despite the low penetrance, hypertrophy was severe in several heterozygotes." This variability — 25-90% depending on the study population — reflects the influence of genetic modifiers, age at assessment, and environmental triggers on phenotypic expression.

At the severe end of the spectrum, a Japanese case series⁹⁹ Japanese case series
Naito et al. 2023, three patients with MYH7 R453 variants — the residue at protein position 453 in the older, alternative numbering that corresponds to Asp906 in current HGVS notation documented rapid progression from preserved ejection fraction to end-stage heart failure, requiring cardiac resynchronization defibrillators, left ventricular assist devices, and transplant listing. Histopathology showed cardiomyocyte disarray and interstitial fibrosis — the classic end-organ signature of HCM progression.

Practical Implications

The central action for any carrier of the C allele is cardiac surveillance: periodic echocardiograms and ECGs, ideally under the care of a cardiomyopathy specialist. The goal is early detection of hypertrophy, outflow tract obstruction, and arrhythmia — all three of which are more manageable when caught before symptoms develop. Competitive sport carries elevated sudden death risk for HCM carriers and requires a specialist evaluation before participation.

Pharmacological options for symptomatic HCM now include myosin inhibitors (mavacamten, aficamten) — drugs designed precisely to counteract the hypercontractile state that MYH7 pathogenic variants produce. These are prescription medications requiring specialist management but represent a mechanism-matched intervention for this class of variant. Beta-blockers and calcium channel blockers remain first-line agents for symptom control and rate management in HCM with obstruction.

Cascade genetic testing in first-degree family members is standard of care. Each child, sibling, or parent of a confirmed carrier has a 50% chance of carrying the same variant; early identification in asymptomatic relatives allows prophylactic monitoring before structural disease develops.

Interactions

HCM phenotype severity from MYH7 pathogenic variants is modified by sarcomeric modifier variants elsewhere in the genome — particularly in genes encoding titin (TTN)¹⁰¹⁰ titin (TTN)
The largest human protein, functioning as the sarcomere's molecular spring and ruler; rare TTN variants can act as independent HCM or DCM causes, alpha-tropomyosin (TPM1, rs117022535), and myosin-binding protein C (MYBPC3). Compound heterozygosity — carrying pathogenic variants in two sarcomeric genes simultaneously — is associated with earlier onset and more severe disease than single-gene HCM. The related variant rs121913625 (MYH7 R453C, Arg453Cys) is a distinct pathogenic HCM mutation at a different residue in the same gene with overlapping but not identical biochemical consequences.

Familial Mediterranean fever (FMF) is an autoinflammatory disease defined by episodic, self-limiting attacks of fever and serositis — sterile inflammation of the abdominal, pleural, or pericardial lining — lasting 12 to 72 hours, then abruptly resolving. Between attacks, most patients feel well. The gene responsible, MEFV, encodes pyrin¹¹ pyrin
a scaffolding protein that assembles the pyrin inflammasome and controls release of IL-1β, the master cytokine of innate immunity. When pathogenic variants impair pyrin's regulatory capacity, inflammasome activation becomes constitutive, triggering unprovoked inflammatory attacks.

V726A (p.Val726Ala, c.2177T>C) is one of five founder mutations²² founder mutations
mutations that arose in a common ancestral population and were then spread as the population migrated; founder mutations are highly enriched in specific ethnic groups that together account for approximately 74% of FMF chromosomes across Armenians, Arabs, Turks, and Sephardic Jews. It sits in exon 10, the hotspot for severe FMF mutations, alongside M694V and M680I. Unlike E148Q (exon 2, which is debated), V726A is unambiguously pathogenic: ClinVar classifies it Pathogenic/Likely pathogenic across 43 of 56 independent submissions with no conflicts.

The Mechanism

Valine at position 726 sits within the B30.2 (SPRY) domain³³ B30.2 (SPRY) domain
the C-terminal regulatory domain of pyrin that senses RhoA GTPase effector signals and microbial toxins, gating inflammasome activation of pyrin. This domain normally maintains pyrin in an autoinhibited, inactive state through interactions with regulatory kinases PKN1 and PKN2. Substituting valine with the smaller, non-polar alanine at position 726 disrupts a stabilizing contact within the B30.2 fold. The result is decreased PKN1/14-3-3 binding and constitutive activation of the pyrin inflammasome — spontaneous caspase-1 cleavage of pro-IL-1β and pro-IL-18, without the microbial trigger normally required.

The severity of this dysfunction is intermediate. Functional studies show V726A pyrin retains more residual regulatory capacity than M694V — quantified as a higher threshold for spontaneous activation. This mechanistic gradient maps directly onto clinical observations: V726A homozygotes have more manageable disease than M694V homozygotes, and respond better to colchicine prophylaxis.

The Evidence

Genotype-phenotype correlation studies across multiple populations consistently rank V726A as intermediate severity. In a cohort of Arab FMF patients, Majeed et al. (2002)⁴⁴ Majeed et al. (2002) documented a mean severity score of 10±3 for V726A/V726A homozygotes versus 14±2 for M694V/M694V (p=0.003), placing V726A clearly below M694V but above M694I (score 6±1). Crucially, the compound heterozygous M694V/V726A genotype was associated with a severe clinical course, indicating that the severity ranking is genotype-specific rather than intrinsic to V726A alone.

Colchicine response data from Lidar et al. (2012)⁵⁵ Lidar et al. (2012) precisely quantifies the treatment gap between genotypes: V726A homozygotes achieved near-complete attack control (mean 0.08±0.20 attacks/year) on modest colchicine doses (1.13±0.41 mg/day), while M694V homozygotes remained partially active (0.70±1.06 attacks/year) despite requiring 1.98 mg/day, with 40% experiencing dose-limiting side effects. This places V726A homozygotes among the most colchicine-responsive MEFV genotypes.

Amyloidosis risk — the most feared long-term complication of FMF — correlates primarily with M694V genotype and duration of inadequately treated inflammation. V726A carriers have substantially lower amyloidosis rates: the largest pediatric cohort study (Öztürk et al. 2022⁶⁶ Öztürk et al. 2022, n=3,454) recorded only 0.3% secondary amyloidosis prevalence across all genotypes in the colchicine era, and the authors attribute this primarily to tight control in M694V-dominant cases. Heterozygous V726A carriers who are clinically asymptomatic are not at elevated amyloidosis risk.

A 30-year retrospective analysis of genotype-phenotype trends (Yildirim et al. 2025⁷⁷ Yildirim et al. 2025) confirmed that V726A was negatively correlated with severe PRAS (physician rating score) across the study period, reinforcing its classification as a milder exon 10 allele compared to M694V.

Practical Implications

For heterozygous carriers with no symptoms, V726A heterozygosity requires no treatment. FMF is autosomal recessive — a single pathogenic allele is generally insufficient to cause full disease. The carrier state may predispose to subclinical inflammation (elevated SAA or CRP between attacks) in some individuals, but this does not meet the threshold for prophylactic colchicine in asymptomatic adults.

For homozygous V726A carriers or compound heterozygotes with another pathogenic MEFV allele: colchicine is the standard of care, initiated as early as diagnosis. The standard prophylactic dose in adults is 0.5–2 mg/day adjusted to attack frequency. V726A genotype predicts a favorable response — most patients achieve full attack suppression at moderate doses. The primary rationale for strict prophylaxis is preventing AA amyloidosis, which requires sustained subclinical inflammation to accumulate serum amyloid A protein in the kidneys. Uncontrolled FMF — even without obvious fever attacks — elevates SAA levels and drives amyloidosis over years to decades. Colchicine normalizes inter-attack SAA in the majority of V726A-genotype patients.

Monitoring should include periodic urinalysis for proteinuria (screening for early renal amyloidosis) and serum SAA measurement to confirm inter-attack inflammatory suppression.

Interactions

V726A interacts meaningfully with other MEFV variants. Compound heterozygosity with M694V (rs61752717) elevates phenotype severity significantly above V726A homozygosity — Majeed et al. classified M694V/V726A as a "severe" genotype, comparable to M694V/M694V in clinical impact. V726A also participates in the complex allele V726A+E148Q (rs3743930), where both mutations sit on the same chromosome: this cis-combination is more severe than V726A alone, suggesting E148Q modifies pyrin function even in a trans-exon context.

For compound heterozygotes with M680I (rs61752720), disease is typically moderate — less severe than M694V/V726A but more active than V726A homozygosity alone. The specific compound genotype determines colchicine dose requirements and the urgency of prophylaxis.

The rs2943634 variant sits in an intergenic region of chromosome 2q36.3, approximately 528 kilobases upstream of the IRS1 gene¹¹ IRS1 gene
insulin receptor substrate 1, a central adaptor protein in insulin and IGF-1 signaling. Despite lying outside any protein-coding sequence, rs2943634 was independently replicated in genome-wide association studies for coronary artery disease²² genome-wide association studies for coronary artery disease
including the landmark Samani et al. 2007 NEJM GWAS and has since been shown to have a broader cardiovascular footprint including ischemic stroke, HDL cholesterol, and adiponectin.

The Mechanism

The SNP does not change any protein sequence. Instead, it likely acts as a regulatory variant³³ regulatory variant
altering gene expression of nearby genes through enhancer elements or chromatin remodeling. The nearest candidate gene is IRS1, encoding a key scaffold protein that transmits insulin and IGF-1 receptor signals to downstream metabolic pathways including PI3K-Akt and MAPK. IRS1 activity influences adiponectin secretion by adipocytes⁴⁴ adiponectin secretion by adipocytes
a cardioprotective adipokine that enhances insulin sensitivity, suppresses endothelial inflammation, and promotes reverse cholesterol transport.

The A allele is associated with higher circulating adiponectin and HDL cholesterol in an additive, dose-dependent manner. Crucially, when Arregui et al. adjusted for both adiponectin and HDL simultaneously⁵⁵ Arregui et al. adjusted for both adiponectin and HDL simultaneously
in mediation analyses within the EPIC-Potsdam cohort, the stroke association persisted, suggesting the variant also engages independent protective mechanisms beyond these two biomarkers.

The Evidence

The 2q36.3 locus was first tagged in the Samani et al. 2007 NEJM genome-wide association study⁶⁶ Samani et al. 2007 NEJM genome-wide association study
a joint analysis of the Wellcome Trust Case Control Consortium and the German MI Family Study, achieving genome-wide significance for coronary artery disease in European populations. The Coronary Artery Disease Consortium 2009⁷⁷ Coronary Artery Disease Consortium 2009
a large-scale multicenter replication study confirmed the locus in independent cohorts.

The most detailed functional analysis came from Arregui et al. 2012⁸⁸ Arregui et al. 2012
a nested case-cohort within the EPIC-Potsdam prospective study of 27,548 middle-aged German adults followed for a mean 8.2 years. The A allele was associated with [a 34% reduction in ischemic stroke risk | HR=0.66, 95% CI 0.50-0.87, P=0.003] in an additive model, while showing no significant association with myocardial infarction (HR=1.02, P=0.83). Adiponectin concentrations rose stepwise: CC 6.94, CA 7.27, AA 7.86 μg/ml (P=0.0002). HDL cholesterol followed the same pattern: CC 52.1, CA 53.1, AA 55.3 mg/dl (P=0.002).

In a broader cardiovascular context, the MORGAM prospective cohort study across N=33,282 participants⁹⁹ MORGAM prospective cohort study across N=33,282 participants
spanning multiple European countries, with 571 incident stroke events also linked rs2943634 to HDL cholesterol and blood pressure. The Dlouha et al. 2025 study in heart transplant recipients¹⁰¹⁰ Dlouha et al. 2025 study in heart transplant recipients
examining accelerated coronary disease post-transplant found the C allele associated with OR 2.46 (95% CI 1.12-6.17) for early cardiac allograft vasculopathy, an accelerated form of CAD that develops uniquely in transplanted hearts.

A 2012 metabolic syndrome study van der Valk et al. in EPIC-NL (N=1,886)¹¹¹¹ van der Valk et al. in EPIC-NL (N=1,886)
testing IRS1 locus variants and metabolic syndrome components found the A allele associated with OR 0.88 (95% CI 0.79-0.97) protection against metabolic syndrome, with significant associations across HDL, triglycerides, and HbA1c.

The evidence is replicated across European cohorts but inconsistently in some smaller studies — the strongest and most consistent signal is for ischemic stroke and HDL cholesterol. Effect sizes are modest (common variant with population-attributable effects), fitting the polygenic architecture of cardiovascular disease.

Practical Implications

Carrying one or two C alleles does not determine your fate — this is one of many common variants that collectively elevate cardiovascular risk. The clinical relevance lies in recognizing that [this genotype lowers circulating adiponectin and HDL | both biomarkers with direct anti-atherogenic and anti-inflammatory effects on the vascular wall]. People with the CC genotype may need to work harder to achieve the same HDL levels as AA carriers, and should be more proactive about monitoring vascular risk factors.

Interactions

rs2943634 co-occurs with other cardiovascular GWAS loci. The chromosome 9p21.3 locus (rs10757274)¹²¹² chromosome 9p21.3 locus (rs10757274)
one of the strongest genetic risk factors for coronary artery disease, near CDKN2A/B was studied alongside rs2943634 in the cardiac transplant study, and the two loci appeared to have additive effects on early allograft vasculopathy. The 6q25.1 locus (rs6922269)¹³¹³ 6q25.1 locus (rs6922269)
an MRAS gene variant associated with CAD has also been grouped with rs2943634 in multi-locus cardiovascular risk studies.